Evidence map›Paper›PMID 37459583›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report.

Cindy Im, Noha Sharafeldin, Yan Yuan, Zhaoming Wang, Yadav Sapkota, Zhanni Lu, Logan G Spector, Rebecca M Howell, Michael A Arnold, Melissa M Hudson and 7 more

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Cindy ImDepartment of Pediatrics, University of Minnesota, Minneapolis, MN.ORCID 0000-0003-0931-9432
Noha SharafeldinHematology Oncology Division, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0001-8835-8899
Yan YuanSchool of Public Health, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0002-2073-9924
Zhaoming WangDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-7556-3869
Yadav SapkotaDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-5943-9454
Zhanni LuDepartment of Pediatrics, University of Minnesota, Minneapolis, MN.ORCID 0000-0001-9957-3527
Logan G SpectorDepartment of Pediatrics, University of Minnesota, Minneapolis, MN.ORCID 0000-0003-2516-0222
Rebecca M HowellDepartment of Radiation Physics, University of Texas at MD Anderson Cancer Center, Houston, TX.
Michael A ArnoldDepartment of Pathology and Laboratory Medicine, University of Colorado and Children's Hospital Colorado, Anschutz Medical Campus, Aurora, CO.
Melissa M HudsonDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-6984-2407
Kirsten K NessDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-2084-1507
Leslie L RobisonDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-7460-8578
Smita BhatiaInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-7755-5683
Gregory T ArmstrongDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.
Joseph P NegliaDepartment of Pediatrics, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-5525-0598
Yutaka YasuiSchool of Public Health, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0002-7717-8638
Lucie M TurcotteDepartment of Pediatrics, University of Minnesota, Minneapolis, MN.ORCID 0000-0003-4106-6172
St. Jude Children's Research Hospital · USUniversity of Minnesota · USUniversity of Alabama at Birmingham · USChildren's Hospital Colorado · USThe University of Texas MD Anderson Cancer Center · USUniversity of Alberta · CA

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Mach-LETSGO: Machine-LEarning of Treatment, Survey, and Genetics towards Obtaining Correct Classification of Chronic Conditions in Adult Survivors in the Childhood Cancer Survivor Study - CCSS SupplU24CA055727 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Gregory Armstrong · 1999 to 2026
$96.7M
The St. Jude Lifetime CohortU01CA195547 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HUDSON, MELISSA M, NESS, KIRSTEN KIMBERLIE · 2015 to 2024
$14.9M
Late Effects Prediction using Clinical Phenotypes and Whole Genome SequencingR01CA216354 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI YASUI, YUTAKA, ZHANG, JINGHUI · 2017 to 2021
$3.4M
Treatment-specific genetic risk scores for late effects prediction in childhood,adolescent, and young adult cancer survivorsR21CA261833 · NCI · UNIVERSITY OF MINNESOTA · PI IM, CINDY, YUAN, YAN · 2021 to 2021
$279k
NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA216354NCI NIH HHS R21 CA261833NCI NIH HHS U01 CA195547NCI NIH HHS U24 CA055727
6 · The paper itself

Abstract

purposeChemotherapeutic exposures are associated with subsequent malignant neoplasm (SMN) risk. The role of genetic susceptibility in chemotherapy-related SMNs should be defined as use of radiation therapy (RT) decreases. PATIENTS AND

methodsSMNs among long-term childhood cancer survivors of European (EUR; N = 9,895) and African (AFR; N = 718) genetic ancestry from the Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study were evaluated. An externally validated 179-variant polygenic risk score (PRS) associated with pleiotropic adult cancer risk from the UK Biobank Study (N > 400,000) was computed for each survivor. SMN cumulative incidence comparing top and bottom PRS quintiles was estimated, along with hazard ratios (HRs) from proportional hazards models.

resultsA total of 1,594 survivors developed SMNs, with basal cell carcinomas (n = 822), breast cancers (n = 235), and thyroid cancers (n = 221) being the most frequent. Although SMN risk associations with the PRS were extremely modest in RT-exposed EUR survivors (HR, 1.22;

conclusionA pleiotropic cancer PRS has strong potential for improving SMN clinical risk stratification among nonirradiated survivors treated with specific chemotherapies. A polygenic risk screening approach may be a valuable complement to an early screening strategy on the basis of treatments and rare cancer-susceptibility mutations.

Indexed as

Breast NeoplasmsCancer SurvivorsNeoplasms, Second PrimaryAdultChildCohort StudiesFemaleHumansPodophyllotoxinRisk FactorsPodophyllotoxin

Identifiers

PMID37459583
PMCPMC10522108
OpenAlexW4384488712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.